Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Sells 9,520 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $65.40, for a total value of $622,608.00. Following the completion of the transaction, the chief operating officer now owns 809,852 shares of the company’s stock, valued at approximately $52,964,320.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total value of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.95, for a total value of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.30, for a total value of $541,055.20.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $65.48 on Friday. ANI Pharmaceuticals, Inc. has a 12 month low of $36.99 and a 12 month high of $70.81. The stock’s 50 day moving average is $64.95 and its 200-day moving average is $58.63. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of 77.95 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $131.65 million for the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of several recent research reports. HC Wainwright upped their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Guggenheim upped their target price on ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Truist Financial upped their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Finally, Capital One Financial started coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $80.00.

Institutional Investors Weigh In On ANI Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in ANI Pharmaceuticals by 93.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the third quarter worth approximately $34,000. Pacer Advisors Inc. acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $41,000. Point72 Asset Management L.P. grew its position in ANI Pharmaceuticals by 60.0% during the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 291 shares in the last quarter. Finally, Coppell Advisory Solutions LLC acquired a new stake in ANI Pharmaceuticals during the second quarter worth approximately $44,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.